NR2B antagonist pursued for treatment-resistant depression.
D017322:Clinical Trials, Phase II as Topic / Q000379:methods; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
D015507:Drugs, Investigational; D018691:Excitatory Amino Acid Antagonists; C121001:NR2B NMDA receptor; D016194:Receptors, N-Methyl-D-Aspartate